NASDAQ:ATYR · NASDAQ Global Market
+$0.07 today
Vol 1.48M · Avg 2.29M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Company filings are the primary source for understanding what changed inside aTyr Pharma, Inc. before the market fully reacts. Review recent ATYR disclosures alongside price history and peer context to identify new risks, accounting changes, strategic updates, capital allocation decisions, and operating details that may affect the intrinsic value case.
Price History
Dividend-adjusted closing price
Change
-88.82%
Period High
$6.61
Period Low
$0.40
Latest
$0.59
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$496.47M
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$236.83M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$172.36M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$92.61M
Precision BioSciences, Inc.
NASDAQ:DTIL
$89.16M
MindWalk Holdings Corp.
NASDAQ:HYFT
$69.60M
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
$51.44M
What is the latest ATYR filing?
The latest filing shown is 8-K dated Jun 8, 2026.
How many recent filings does ATYR have?
Intrinsic Alpha currently shows 20 recent filings for ATYR.
Explore More
Continue the stock analysis
Jump to another research area for this company.